Weighted Gene Co-Expression Network Analysis to Construct Competitive Endogenous RNAs Network in Chromogenic Renal Cell Carcinoma

Yon-Bo Chen  
Peoples Hospital of Deyang City

Liang Gao  
the second affiliated hospital of chongqing medical university

Liang-You Tang  
Peoples Hospital of Deyang City

Yu-Chang Tian  
Peoples Hospital of Deyang City

Guan-Qiang Tian  
Peoples Hospital of Deyang City

PingHong You (✉ yamyou@126.com)  
Peoples Hospital of Deyang City  https://orcid.org/0000-0002-0521-5399

Research article

Keywords: ceRNA, ChRCC, WGCNA, biomarkers

DOI: https://doi.org/10.21203/rs.3.rs-74771/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: This study aimed to construct the competing endogenous RNA (ceRNA) network in chromophobe renal cell carcinoma (ChRCC).

Methods: Clinical and RNA sequence profiles of patients with ChRCC, including messenger RNAs (mRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs), were obtained from The Cancer Genome Atlas (TCGA) database. “EdgeR” and “clusterProfiler” packages were utilized to obtain the expression matrices of differential RNAs (DERNAs) and to conduct gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Weighted gene co-expression network analysis (WGCNA) was performed to screen the highly related RNAs, and miRcode, StarBase, miRTarBase, miRDB, and TargetScan datasets were used to predict the connections between them. Univariate and multivariate Cox proportional hazards regressions were performed in turn to elucidate prognosis-related mRNAs in order to construct the ceRNA regulatory network.

Results: A total of 1628 DElncRNAs, 104 DEmiRNAs, and 2619 DEmRNAs were identified. WGCNA showed significant correlation in 1534 DElncRNAs, 98 DEmiRNAs, and 2543 DEmRNAs, which were related to ChRCC. Fourteen DEmiRNAs, 113 DElncRNAs, and 43 DEmRNAs were screened. Nine mRNAs (ALPL, ARHGAP29, CADM2, KIT, KLRD1, MYBL1, PSD3, SFRP1, SLC7A11) significantly contributed to the overall survival (OS) of patients with ChRCC (P < 0.05). Furthermore, two mRNAs (CADM2, SFRP1) appeared to be independent risk factors for ChRCC.

Conclusion: The findings revealed the molecular mechanism of ChRCC and potential therapeutic targets for the disease.

Introduction

As one of the three major renal cell carcinoma histological subtypes, chromophobe renal cell carcinoma (ChRCC), accounts for 4–5% of renal cancer cases [1]. The average diagnostic age of ChRCC is 58 years, and most patients are male [2]. Most patients with ChRCC have good prognoses with 5-year survival rates of 78–100%. However, metastases still occur in about 6–7% of patients and usually affect the liver or lungs [3]. Furman and Panel tumor classification schemes have already been proposed for use in staging ChRCC over the past decades [4, 5]. However, considering the ambiguity of the grading criteria and the lack of applicability to the characteristics of the nucleus of ChRCC, their prognostic value appears to have been overestimated [6, 7]. In order to better standardize treatment and improve patient prognosis, it is critical to elucidate highly specific biomarkers and effective therapeutic targets. In 2011, Salmena et al. described the competing endogenous RNA (ceRNA) hypothesis, which re-explored the regulatory function of long noncoding RNAs and the potential network between messenger RNAs (mRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs) [8]. As a key element in the ceRNA network, miRNAs could simultaneously be competitively antagonized by lncRNA, mRNA, and other RNAs through shared microRNA response elements (MREs). Overexpressed MRE-containing transcripts (so-called “RNA
sponges”) could affect expression by absorbing multiple miRNAs connected to mRNAs [9–11]. This molecular internal regulation mechanism plays an important role in the occurrence and development of multiple cancers [12]. The Cancer Genome Atlas (TCGA) database, established by the National Cancer Institute and the National Human Genome Research Institute, has collected numerous genomic, epigenomic, transcriptomic, and proteomic data for 33 cancer types [13, 14], facilitating exploration of the ceRNA network in ChRCC and the identification of prognostic related biomarkers.

**Materials And Methods**

All clinical and RNA sequence profile data of patients enrolled in the TCGA database before May 2020, including mRNA, miRNA, and IncRNA matrices, were completely downloaded and extracted from the dataset (https://portal.gdc.cancer.gov/). Inclusion criteria stipulated that the clinical data of every sample should, at least, include the patient’s survival status and survival time. R version 3.6.0 software was used for all statistical analyses. As a public database was used, additional approval from an ethics committee was not required.

The “edgeR” package of R (version 3.6.0) was used to elucidate and compare the DElncRNAs, DEmiRNAs and DEmRNAs of normal and cancer samples. Log2FC > 2 and FDR < 0.05 were considered statistically significant. We performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses using the “ClusterProfiler” package (with P < 0.05 as significant) to construct the pathways-genes and pathways-pathways networks. [15].

After verifying and confirming the optimal soft threshold, we conducted weighted gene co-expression network analysis (WGCNA) using the “WGCNA” package. RNAs were classified into different color modules according to the connectivity and synergy between them. In selecting the RNAs for next analyses, connectivity was established between each module and the relevant ChRCC trait.

The IncRNAs-miRNAs matrices in selected modules were predicted and simplified in miRcode (http://www.mircode.org/) and their associations obtained. These miRNAs were predicted using StarBase (http://starbase.sysu.edu.cn/), miRTarBase (http://miRTarBase.mbc.ntu.edu.tw/), miRDB (http://www.mirdb.org/), and TargetScan (http://www.targetscan.org/) datasets in order to obtain their target mRNAs. The mRNAs from selected modules were combined with the target mRNAs to exclude unrelated mRNAs.

Finally, univariate and multivariate Cox proportional hazards regressions were performed in turn using the “survival” package of R to elucidate the most significant independent risk factor mRNAs associated with the OS of patients with ChRCC. Sample scores were compared to the median risk score and divided into high-risk and low-risk groups. ROC and C-indices were used to evaluate the stability and reliability of the mRNA-based prognostic model. The detailed flow chart is presented in Fig. 1.

Based on the elucidated relationships between lncRNAs-miRNAs and miRNAs-mRNAs, and the Cox results, we were able to derive the lncRNAs-miRNAs-mRNAs competing endogenous network. Cytoscape
software (version of 3.6.1) was used to visualize the ceRNA network. The Kaplan–Meier curves were used to analyze the reliability with which each RNA in the ceRNA network was able to predict the patient's OS (with P < 0.05 indicating significant reliability).

## Results

The lncRNAs, miRNAs and mRNAs expression matrices of the 89 patients (24 normal and 65 with ChRCC) were downloaded from the TCGA dataset. Patients’ clinicopathological characteristics are presented in Table 1.

|                         | Total(n = 65) | Alive(n = 55) | Dead(n = 10) |
|-------------------------|---------------|---------------|--------------|
| **Gender**              |               |               |              |
| Male                    | 39            | 32            | 7            |
| Female                  | 26            | 23            | 3            |
| **Race**                |               |               |              |
| Asian                   | 2             | 1             | 1            |
| White                   | 57            | 48            | 9            |
| Black or african American| 4             | 4             | 0            |
| Not reported            | 2             | 2             | 0            |
| **Age at diagnose**     |               |               |              |
| < 60 (years)            | 46            | 41            | 5            |
| 60–80 (years)           | 18            | 13            | 5            |
| > 80 (years)            | 1             | 1             | 0            |
| Mean (SD) (days)        | 19129.83 (5127.97) | 18493.20 (4978.49) | 22631.30 (4709.89) |
| Median [MIN, MAX] (days)| 18502 [6556, 31591] | 17710 [6556, 31591] | 22697 [15045, 28705] |
| **Tumor clinical stage**|               |               |              |
| Stage_I                 | 20            | 19            | 1            |
| Stage_II                | 25            | 23            | 2            |
| Stage_III               | 14            | 11            | 3            |
| Stage_IV                | 6             | 2             | 4            |
Firstly, 1628 DElncRNAs (763/865, up/down), 104 DEmiRNAs (61/43, up/down), and 2619 DEmRNAs (1103/1516, up-/down-DEmRNAs), were elucidated. Their volcano maps and heatmaps are presented in Fig. 2 (A, B, C). GO analysis showed that the top five functions of the 2619 DEmRNAs focused on organic anion transport, regulation of membrane potential, regulation of ion transmembrane transport, modulation of chemical synaptic transmission, and regulation of trans-synaptic signaling (Fig. 3A). Meanwhile, the top five KEGG pathways of these DEmRNAs were enriched in neuroactive ligand-receptor interaction, cAMP signaling pathway, complement and coagulation cascades, retinol metabolism, and chemical carcinogenesis (Fig. 3B). Insulin secretion and connection between pathways were presented in the pathways-pathways network (Fig. 3C). In the pathways-genes network, multiple RNAs were related to five pathways: complement and coagulation cascades, metabolism of xenobiotics by cytochrome P450, neuroactive ligand-receptor interaction, retinol metabolism, and steroid hormone biosynthesis (Fig. 3D).

In the WGCNA, the power of the soft threshold of the lncRNAs-miRNAs matrix was 10 (Fig. 4A), and the miRNAs-mRNAs matrix was 14 (Fig. 4B), both of which achieved the best satisfaction and consistency of the scale-free R-squared value. After calculating their adjacency and connectivity, these lncRNAs-miRNAs were classified into 10 modules (Fig. 4C), and miRNAs-mRNAs were classified into 11 modules (Fig. 4D). Their topological overlap matrix heatmaps are presented in Fig. 4 (E, F). Red, yellow, brown, and grey modules of lncRNAs-miRNAs were found to have significant correlation (Fig. 5A), and greater connections were also observed in green, turquoise, and grey modules of the miRNAs-mRNAs (Fig. 5B). Modules in these two groups included a total of 1534 DElncRNAs, 98 DEmiRNAs, and 2543 DEmRNAs, which were also more closely related to ChRCC than the others (Fig. 5C, D).

When predicting the DElncRNAs and DEmiRNAs of the module genes in miRcode, we identified 116 DElncRNAs (43/73, up/down) and 19 DEmiRNAs (9/10, up/down) and their connective pairs. When using the StarBase, mirTarBase, miRDB, and TargetScan datasets, 512 target mRNAs of the 19 DEmiRNAs were included. Forty-three of them finally coincided with selected module DEmRNAs (Fig. 5E), which corresponded to 113 lncRNAs and 14 miRNAs.

Nine mRNAs (ALPL, ARHGAP29, CADM2, KIT, KLRD1, MYBL1, PSD3, SFRP1, SLC7A11) were identified as prognosis-related genes when an univariate Cox analysis was conducted on the 43 mRNAs, (P < 0.05). Moreover, the results of multivariate Cox proportional hazards regressions indicted that two of the nine mRNAs (CADM2, SFRP1) were independent risk factors for ChRCC (Fig. 6A). The C-index of this model was 0.91, and the 3-and 5-year AUCs (area under receiver operating characteristic curve) were 0.996 and 0.989 (Fig. 6B), which proved the stability and reliability of the model. Finally, six miRNAs (3/3, up/down) corresponded to 79 lncRNAs (31/48, up/down) and were associated with these nine mRNAs (5/4, up/down). The ceRNA network based on their relationship was constructed using the Cytoscape platform (Fig. 7A).

Additionally, Kaplan–Meier analyses for the ceRNA members showed that low expression of KLRD1 and high expression of LINC00520 significantly contributed to worse OS for patients with ChRCC (P < 0.05).
Meanwhile, the low-risk group also showed obvious superiority over the high-risk group, despite its P value being slightly greater than 0.05 (P = 0.06016) (Fig. 7D).

**Discussion**

With the progress of molecular biology, the function of noncoding transcriptome has been extensively explored. Multi-RNAs competition regulatory networks appear to play indispensable roles in the biological processes and courses of cancer diseases [16, 17]. Several studies have explored and verified ceRNA networks in the past. Wang JD et al. included 407 normal and 151 acute myeloid leukemia (AML) samples from Genotype-Tissue Expression (GTEx) (https://commonfund.nih.gov/GTEx/) and TCGA datasets in their study. They found that the ceRNA network in AML involved 108 IncRNAs, 10 miRNAs, and 8 mRNAs, which appeared to influence prognosis and cancer progression [18]. Meanwhile, Yao Y et al. also established a ceRNA network from TCGA database comprising 52 IncRNAs, 17 miRNAs, and 79 mRNAs in breast cancer's RNAs matrix and in which five IncRNAs were found to significantly affect patients' OS. Furthermore, results of GO and KEGG analyses of these mRNAs were also related to biological characteristics of tumors [19].

WGCNA is a bioinformatic and sensitive method, which is especially suitable for these large and high-dimensional data, as well as for low abundance or fold change genes. It is able to cluster highly related genes from microarray samples into different color modules and explore the relationship between the genes and cancer traits [20]. WGCNA has already been used in various oncological studies to explore hub genes and the regulatory relationships between them [21–23]. In our study, we performed WGCNA to select highly related module genes, which helped us elucidate the more meaningful RNAs for further prediction.

Importantly, prediction in multiple datasets allowed us to rapidly lockdown the shared high-value genes similar to previous studies [24–27]. Another advantage of our study was the application of univariate and multivariate Cox proportional hazards regressions on selected target mRNAs from which we obtained a reliable and stable prognostic model and identified important genetic biomarkers for ChRCC within the ceRNAs network. The excellent C-index and 3- and 5-year survival AUCs further proved the superiority of our model. The Kaplan–Meier curves showed that low-risk patients would achieve better long-term OS.

A member of the cell adhesion molecule gene family, CADM2, has been reported to be under-expressed in the nine mRNAs. This might contribute to the progression of various cancers, including prostate cancer, ovarian cancer, lymphoma, melanoma, and clear renal cell cancer (cRCC) [28–32]. CADM2 is believed to prevent tumor progression, invasion and metastasis by maintaining cell’s polarity and adhesion [32].

Tyrosine protein kinase (KIT) is overexpressed in various cancers [33, 34]. Especially in ChRCC and oncocytoma. Huo L et al. reported that KIT was more sensitive to ChRCC and oncocytoma than other renal cancers, and hence it would be useful in precise tumor classification and targeted therapy [35, 36]. In the past, SFRP1 has been considered to be a tumor suppressor gene and possibly antagonistic to the wnt signaling pathway [37]. It has been found that increased methylation levels in the SFRP1 promoter
region might lead to SFRP1 silencing in Crcc [38, 39]. Meanwhile, low SLC7A11 expression was found to be an important target in the p53 tumor suppression pathway, which is closely related to cell-cycle arrest, apoptosis, and senescence. As the main component of the cystine/glutamate antiporter, under-expressed SLC7A11 could inhibit cellular uptake of cystine and eventually lead to increased cell sensitivity to ferroptosis [40]. Additionally, upregulation of ARHGAP29 might be related to metastasis in gastric cancer [41]. ALPL is primarily related to hypophosphatemia [42]. SR Rao et al. found that high expression of ALPL led to poor survival outcomes for patients with prostate cancer [43]. However, another study proposed that ALPL could inhibit the motility and aggression of serous ovarian cancer cells [44]. High expression of KLRD1 was reported to inhibit the function of natural killer cells and cytokine induced killer cells [45, 46]. PSD3 is considered to be a candidate metastasis suppressor gene, and its low expression has been observed to be associated with poor prognosis in ovarian cancer and metastasis in breast cancer [47, 48]. Moreover, MYBL1 is highly expressed in adenoid cystic carcinoma and is often accompanied by genomic rearrangements [49]. These previous findings lend confidence to the hypothesis that the ceRNA network plays an important role in the occurrence and development of cancers. Moreover, to our knowledge, this is the first report regarding the role of these mRNAs in the ChRCC, in which KLRD1 was found by Kaplan–Meier analysis (P = 2.344e-2) to significantly affect patients’ OS.

Previous studies involving cRCC have reported the importance of the six miRNAs (hsa-mir-222, hsa-mir-204, hsa-mir-206, hsa-mir-183, hsa-mir-372, hsa-mir-221) in the ceRNA network. In particular, hsa-mir-206, hsa-mir-204, and hsa-mir-372 were found to suppress cancer through corresponding biological functions [50–52], and hsa-mir-183 was considered to be a potential oncogene [53]. Kaplan–Meier analysis also showed that high expression of LINC00520 had an effect on OS. Chen B et al. in their study based on the cBioPortal dataset, also emphasized its importance in cRCC [54]. However, more studies are needed to fully explore the biological function of the lncRNAs in ChRCC.

In this study, we constructed a ceRNA network including 79 lncRNAs, 6 miRNAs, and 9 mRNAs. Their possible competitive synergistic biological functions might jointly regulate various processes in ChRCC, and, hence, they may provide new therapeutic targets and a new perspective for ChRCC genetic biology studies. However, there were some limitations to our study. Firstly, the prognostic model of mRNA has not been externally verified. Also, we lacked in vivo and in vitro experiments to verify our results.

**Conclusion**

In this study, we established the ceRNA network in ChRCC, which included 79 lncRNAs, 6 miRNAs, and 9 mRNAs. Among them, three mRNAs (CADM2, SFRP1, KLRD1) and one lncRNA (LINC00520) showed promise as potential biomarkers for ChRCC. Our results offer new insights into the diagnosis and treatment of ChRCC and demonstrate the merit of further genetic biology research into ChRCC.

**Declarations**
ACKNOWLEDGEMENTS

We would like to thank The Cancer Genome Atlas (TCGA) database.

AUTHORS’ CONTRIBUTIONS

Yong-Bo Chen, Liang Gao and Ping-Hong You designed the study. Yong-Bo Chen and Liang-You Tang selected and analysed the data. Yong-Bo Chen, Guan-Qiang Tian and Yu-Chang Tian involved in statistical analysis. Yong-Bo Chen, Liang Gao, Liang-You Tang and Ping-Hong You drafted and revised the manuscript. All authors have reviewed and approved the final manuscript.

FUNDING

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The dataset supporting the conclusions of this study is available in The Cancer Genome Atlas (TCGA) database.

ETHICS APPROVAL

Not applicable.

CONSENT FOR PUBLICATION

Not applicable.

COMPETING OF INTERESTS

The authors declare that they have no conflict of interest.

References

1. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75:799–810.
2. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016;70:93–105.
3. Erlmeie F. Chromophobe renal cell carcinoma-diagnosis and prognosis. Pathologe. 2019;40:252–8.
4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–63.
5. Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol. 2010;34:1233–40.

6. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer. 2000;89:604–14.

7. Pérez-Pedrosa A, Ortiz-Rey JA, Lorenzo-Mahía Y, Iglesias-Rodríguez B, Peteiro-Cancelo A, González-Carreró J. Interobserver reproducibility of a grading system for chromophobe renal cell carcinoma. Actas Urol Esp. 2013;37:338–41.

8. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA. language? Cell. 2011;146:353–8.

9. Selbach M, Schwannhäuser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58–63.

10. Qi X, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. CeRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52:710–8.

11. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17:272–83.

12. Chan JJ, Tay Y. Noncoding RNA. RNA Regulatory Networks in Cancer. Int J Mol Sci. 2018;19:1310.

13. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19:A68–77.

14. Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16:539–52.

15. Yu GC, Wang LG, Han YY, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–7.

16. Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3:1113–21.

17. An Y, Furber KL, Ji S. Pseudogenes regulate parental gene expression via ceRNA network. J Cell Mol Med. 2017;21:185–92.

18. Wang JD, Zhou HS, Tu XX, He Y, Liu QF, Liu Q, et al. Prediction of competing endogenous RNA coexpression network as prognostic markers in AML. Aging. 2019;11:3333–47.

19. Yao Y, Zhang T, Qi L, Zhou C, Wei J, Feng F, et al. Integrated analysis of co-expression and ceRNA network identifies five IncRNAs as prognostic markers for breast cancer. J Cell Mol Med. 2019;23:8410–9.

20. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.

21. Deng J, Kong W, Mou X, Wang S, Zeng W. Identifying novel candidate biomarkers of RCC based on WGCNA analysis. Per Med. 2018;15:381–94.
22. Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, et al. Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel). 2019;12:37.

23. Xia WX, Yu Q, Li GH, Liu YW, Xiao FH, Yang LQ, et al. Identification of four hub genes associated with adrenocortical carcinoma progression by WGCNA. PeerJ. 2019;7:e6555.

24. Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46:D296–302.

25. Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 2012;28:2062–3.

26. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127–31.

27. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.

28. He W, Li X, Xu S, Ai J, Gong Y, Gregg JL, et al. Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun. 2013;435:526–32.

29. Chang G, Xu S, Dhir R, Chandran U, O’Keefe DS, Greenberg NM, et al. Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Clin Cancer Res. 2010;16:5390–401.

30. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, et al. Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog. 2009;48:1077–92.

31. Lake SL, Coupland SE, Taktak AF, Damato BE. Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51:4884–91.

32. Roy D, Sin SH, Damania B, Dittmer DP. Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood. 2011;118:e32-9.

33. Isozaki K, Hirota S, Nakama A, Miyagawa J, Shinomura Y, Xu Z, et al. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology. 1995;109:456–64.

34. Duffaud F, Blay J. Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003;65:187–97.

35. Huo L, Sugimura J, Tretiakova MS, Patton KT, Gupta R, Popov B, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36:262–8.

36. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol. 2004;121:878–83.
37. Mo S, Su Z, Heng B, Chen W, Shi L, Du X, et al. SFRP1 Promoter Methylation and Renal Carcinoma Risk: A Systematic Review and Meta-Analysis. J Nippon Med Sch. 2018;85:78–86.

38. Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Methylation-associated silencing of SFRP1 in renal cell carcinoma. Oncol Rep. 2008;20:1257–63.

39. Atschekzei F, Hennenlotter J, Jänisch S, Großhennig A, Tränkenschuh W, Waalkes S, et al. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. Epigenetics. 2012;7:447–57.

40. Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57–62.

41. Qiao Y, Chen J, Lim YB, Finch-Edmondson ML, Seshachalam VP, Qin L, et al. YAP Regulates Actin Dynamics through ARHGAP29 and Promotes Metastasis. Cell Rep. 2017;19:1495–502.

42. Mornet E, Hypophosphatasia. Metabolism. 2018;82:142–55.

43. Rao SR, Snaith AE, Marino D, Cheng X, Lwin ST, Orriss IR, et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br J Cancer. 2017;116:227–36.

44. Luo M, Zhou L, Zhan SJ, Cheng LJ, Li RN, Wang H, et al. ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical WNT pathway. Biochem Biophys Res Commun. 2019;513:528–33.

45. Wu M, Mei F, Liu W, Jiang J. Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. Biomed Pharmacother. 2020;121:109637.

46. Wang W, Li R, Meng M, Wei C, Xie Y, Zhang Y, et al. MicroRNA profiling of CD3+CD56+ cytokine-induced killer cells. Sci Rep. 2015;5:9571.

47. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat. 2009;113:239–49.

48. Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus VJ, et al. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer. 2005;104:2417–29.

49. Togashi Y, Dobashi A, Sakata S, Sato Y, Baba S, Seto A, et al. MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts. Mod Pathol. 2018;31:934–46.

50. Xiao H, Xiao W, Cao J, Li H, Guan W, Guo X, et al. miR-206 functions as a novel cell cycle regulator and tumor suppressor in clear-cell renal cell carcinoma. Cancer Lett. 2016;374:107–16.

51. Xiong F, Liu K, Zhang F, Sha K, Wang X, Guo X, et al. MiR-204 inhibits the proliferation and invasion of renal cell carcinoma by inhibiting RAB22A expression. Oncol Rep. 2016;35:3000–8.

52. Huang X, Huang M, Kong L, Li Y. miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. Cell Prolif. 2015;48:593–9.
53. Qin S, Shi X, Wang C, Jin P, Ma F. Transcription Factor and miRNA Interplays Can Manifest the Survival of ccRCC Patients. Cancers (Basel). 2019;11:1668.

54. Chen B, Wang C, Zhang J, Zhou Y, Hu W, Guo T. New insights into long noncoding RNAs and pseudogenes in prognosis of renal cell carcinoma. Cancer Cell Int. 2018;18:157.

**Figures**
Figure 1

The flow chart of this study

Figure 2

heatmap and volcano map of lncRNAs (A), miRNAs (B) and mRNAs (C).

heatmap and volcano map of lncRNAs

heatmap and volcano map of miRNAs

heatmap and volcano map of mRNAs
Figure 3

GO (A) and KEGG (B) analysis, pathways-pathways network (C) and pathways-genes network (D) based on the 2619 DEmRNAs.
Figure 4

the power of the soft threshold of the lncRNAs-miRNAs matrix (A), and the miRNAs-mRNAs matrix (B); module classification of the lncRNAs-miRNAs matrix (C), and the miRNAs-mRNAs matrix (D); the topological overlap matrix heatmaps of the lncRNAs-miRNAs matrix (E), and the miRNAs-mRNAs matrix (F).
Figure 5

relationship between module eigengenes of the IncRNAs-miRNAs matrix (A), and the miRNAs-mRNAs matrix (B); module-trait relationships of the IncRNAs-miRNAs matrix (C), and the miRNAs-mRNAs matrix (D); shared mRNAs when predicted (E).
Figure 6

univariate and multivariate Cox analyses based on the 43 mRNAs (A); the receiver operating characteristic curve of the model (B).
Figure 7

the ceRNA network of ChRCC (A); Kaplan–Meier curves of KLRD1 (B), LINC00520 (C) and risk score (D).